

Amendments to claims:

1-32 (cancelled)

33. (new) A method for reducing the average size of biologically active compound solid particles or agglomerates suspended in a liquid by flowing one or more times said liquid having biologically active compound solid particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound solid particles or agglomerates by at least 25%, wherein the linear flow rate of said liquid through each said magnetic field is between 0.25 and 25 m/s.
34. (new) A method according to claim 33, wherein the strength of each said magnetic field is at least about 2,000 gauss.
35. (new) A method according to claim 33, wherein the average size of said biologically active compound solid agglomerates before performing said method is in a range from 10 μm to 100 μm .
36. (new) A method according to claim 33, wherein the average size of a substantial portion of said biologically active compound solid agglomerates after performing said method is reduced to a range from about 0.45 μm to 5 μm .
37. (new) A method according to claim 33, wherein said substantial portion is at least 50% by weight of the suspended solid agglomerates.

38. (new) A method according to claim 33, wherein the average particle size of said biologically active compound solid particles before performing said method is in a range from 0.5 μm to 10 μm .
39. (new) A method according to claim 33, wherein the average particle size of said biologically active compound solid particles after performing said method is reduced to a range from 0.5 nm to 500 nm.
40. (new) A method according to claim 33, wherein said liquid is water or an organic solvent or a combination thereof with water.
41. (new) A method according to claim 33, wherein said biologically active compound solid particles or agglomerates are suspended in said liquid in the form of a slurry and the concentration of said biologically active compound solid particles or agglomerates in said liquid is at least two times the solubility limit of said biologically active compound in said liquid under the physical (temperature, pressure) and chemical (pH) conditions prevailing while flowing said slurry through said magnetic field.
42. (new) A method according to claim 33, wherein said liquid includes one or more stabilizing agents.

43. (new) A method according to claim 33, wherein the residence time of said liquid through each said magnetic field is between 60 microseconds and 10 seconds.

44. (new) A method according to claim 33, wherein the biologically active compound is in a crystalline form or an amorphous form.

45. (new) A method according to claim 33, wherein the biologically active compound is a drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System.

—

46. (new) A method according to claim 33, wherein the biologically active compound is a drug having a water-solubility below 2 mg/ml.

47. (new) A method according to claim 33, wherein the biologically active compound is a cosmetic agent, a diagnostic agent, a herbicide, an insecticide, a biocide or a fungicide.

48. (new) A process for manufacturing a biologically active compound formulation, said biologically active compound being in the form of solid particles or agglomerates, said process comprising a step of reducing by at least 25% the average size of a substantial portion of said biologically active compound solid particles or agglomerates by suspending them in a liquid and by flowing one or more times said liquid having biologically active compound solid particles or agglomerates suspended therein through one or more magnetic fields.

49. (new) A process according to claim 48, wherein said process further comprises one or more post-processing steps performed following the size reducing step.

50. (new) A process according to claim 48, wherein said post-processing step is a drying step for substantially removing the liquid in which the biologically active compound solid particles or agglomerates are suspended during the size reducing step.

51. (new) A process according to claim 48, wherein said post-processing step comprises mixing an adjuvant together with the optionally dried particles or agglomerates with reduced size.

52. (new) A process according to claim 48, wherein said biologically active compound is a drug having a water-solubility below 2 mg/ml.

53. (new) A process according to claim 48, wherein said biologically active compound is a cosmetic agent, a diagnostic agent, a herbicide, an insecticide, a biocide or a fungicide.